Magnetic nanoparticle and method for imaging t cells

US2016193369A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016193369-A1
Application numberUS-201615066717-A
CountryUS
Kind codeA1
Filing dateMar 10, 2016
Priority dateApr 9, 2008
Publication dateJul 7, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides nanoparticles having a core comprising a magnetic material and having a surface, where the surface may be operatively linked to an antigenic peptide-major histocompatibility complex (MHC) monomer. The antigenic peptide-MHC monomer may then be recognized by a T cell receptor. These nanoparticles may further comprise a signal-generating label, such as a fluorophore. Methods employing nanoparticles of the present invention may involve magnetic resonance imaging and/or fluorescence detection, such that cell imaging and localization are performed.

First claim

Opening claim text (preview).

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1 . A method of detecting the presence of cells having a T cell receptor in a sample, comprising: (a) contacting the sample with a nanoparticle comprising: (i) a core comprising a magnetic material and having a surface; and (ii) an antigenic peptide-major histocompatibility complex (MHC) monomer operatively linked to the surface, wherein the antigenic peptide-MHC monomer is recognized by the T cell receptor; and (b) measuring the level of nanoparticle binding to cells in the sample using magnetic resonance imaging. 2 . The method of claim 1 , wherein the cells are tumor cell-specific cytotoxic T cells. 3 . The method of claim 1 , wherein the cells are in vitro, ex vivo, or wherein the sample is a tissue. 4 . The method of claim 1 , wherein the magnetic material is selected from the group consisting of ferrous oxide, ferric oxide, silicon oxide, polycrystalline silicon oxide, silicon nitride, aluminum oxide, germanium oxide, zinc selenide, tin dioxide, titanium, titanium dioxide, indium tin oxide, gadolinium oxide and stainless steel. 5 . The method of claim 1 , wherein the magnetic material is a doped nanoparticle. 6 . The method of claim 5 , wherein the doped nanoparticle is selected from the group consisting of nickel titanium, MnFeO 4 , CoFe 2 O 4 , and NiFe 2 O 4 . 7 . The method of claim 1 , wherein the antigenic peptide is selected from the group consisting of pmel-1, HA-1, MART-1, gp100, NY-ESO-1, WT-1, GAD65, CMV pp65, EBNA, LMP2, HIV-gag, BCR-ABL, Mart2, Mum-1, Mum-2, Mum-3, Bage-1, Gage 3, Gage 4, Gage 5, Gage 6, Gage 7, GnTV, Herv-K-mel, Lage-1, Mage-A1, Mage-A 2, Mage-A 3, Mage-A 4, Mage-A 6, Mage-A 10, Mage-A 12, Mage-C2, NA-88, SP17, SSX-2, TRP2-Int2, TRP-1, TRP-2, MACE-1, p15(58), CEA, RAGE, SCP-1, Hom/Mel-40, PRAME, HER-2/neu, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, human papillomavirus (HPV) antigens E6 and E7, TSP-180, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, p16, TAGE, PSMA, PSCA, CT7, telomerase, 43-9F, 5T4, 791Tgp72, 13HCG, BCA225, BTAA, CA 125, CA 15-3, CA 27.29, CA 195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, G250, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB\70K, NY-CO-1, RCAS1, SDCCAG16, TAAL6, TAG72, TLP, DKK1, EZH2, ALDH1A1, and TPS. 8 . The method of claim 1 , wherein the nanoparticle further comprises a polymer that forms a coating on the surface, and the antigenic peptide-MHC monomer is operatively linked to the polymer. 9 . The method of claim 8 , wherein the nanoparticle has a hydrodynamic size of about 5-300 nm. 10 . The method of claim 8 , wherein the polymer that forms a coating on the surface is covalently bound to the surface. 11 . The method of claim 8 , wherein the polymer that forms a coating on the surface is physically adsorbed to the surface. 12 . The method of claim 8 , wherein the polymer is selected from the group consisting of poly(ethylene glycol) (PEG), chitosan, and chitosan-PEG. 13 . The method of claim 8 , wherein the polymer is covalently bound to an avidin protein. 14 . The method of claim 13 , wherein the antigenic peptide-MHC monomer further comprises biotin and is bound to the avidin protein through a biotin/avidin interaction. 15 . The method of claim 1 , further comprising a signal-generating label. 16 . The method of claim 15 , wherein the signal-generating label is a fluorophore, a chromophore, or a radiolabel. 17 . A method of detecting the presence of cells having a T cell receptor in a subject, comprising: (a) administering to the subject a nanoparticle comprising: (i) a core comprising a magnetic material and having a surface; and (ii) an antigenic peptide-major histocompatibility complex (MHC) monomer operatively linked to the surface, wherein the antigenic peptide-MHC monomer is recognized by the T cell receptor; and (b) measuring the level of nanoparticle binding to cells in the subject using magnetic resonance imaging. 18 . The method of claim 17 , wherein administration is by intravenous injection or intratumoral injection. 19 . A method of detecting the presence of cells having a T cell receptor in a sample, comprising: (a) contacting the sample with a nanoparticle comprising: (i) a core comprising a magnetic material and having a surface; (ii) an antigenic peptide-major histocompatibility complex (MHC) monomer operatively linked to the surface, wherein the antigenic peptide-MHC monomer is recognized by the T cell receptor; and (iii) a fluorophore; (b) isolating those cells from the sample that bound to the nanoparticle; and (c) measuring the level of nanoparticle binding to cells in the sample using fluorescence detection.

Assignees

Inventors

Classifications

  • Magnetic particles · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • White blood cells · CPC title

  • Immunomodulators · CPC title

  • the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016193369A1 cover?
The present invention provides nanoparticles having a core comprising a magnetic material and having a surface, where the surface may be operatively linked to an antigenic peptide-major histocompatibility complex (MHC) monomer. The antigenic peptide-MHC monomer may then be recognized by a T cell receptor. These nanoparticles may further comprise a signal-generating label, such as a fluorophore.…
Who is the assignee on this patent?
Univ Washington, Hutchinson Fred Cancer Res
What technology area does this patent fall under?
Primary CPC classification A61K49/14. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Jul 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).